These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23284638)

  • 1. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
    Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
    Kinders RJ; Hollingshead M; Lawrence S; Ji J; Tabb B; Bonner WM; Pommier Y; Rubinstein L; Evrard YA; Parchment RE; Tomaszewski J; Doroshow JH;
    Clin Cancer Res; 2010 Nov; 16(22):5447-57. PubMed ID: 20924131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
    Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
    Mol Autism; 2018; 9():45. PubMed ID: 30140420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT; Kaina B
    Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
    D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
    Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
    Pfister TD; Reinhold WC; Agama K; Gupta S; Khin SA; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2009 Jul; 8(7):1878-84. PubMed ID: 19584232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
    BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 10. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
    Ji J; Kinders RJ; Zhang Y; Rubinstein L; Kummar S; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2011; 6(10):e26152. PubMed ID: 22028822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
    J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
    Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
    Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors.
    Seol Y; Zhang H; Agama K; Lorence N; Pommier Y; Neuman KC
    Mol Cancer Ther; 2015 Nov; 14(11):2552-9. PubMed ID: 26351326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
    Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
    Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
    Pommier Y; Cushman M
    Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
    Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
    Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
    J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1.
    Dyrkheeva NS; Filimonov AS; Luzina OA; Orlova KA; Chernyshova IA; Kornienko TE; Malakhova AA; Medvedev SP; Zakharenko AL; Ilina ES; Anarbaev RO; Naumenko KN; Klabenkova KV; Burakova EA; Stetsenko DA; Zakian SM; Salakhutdinov NF; Lavrik OI
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.